You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Demographics and clinical characteristics stratified by infection outcomes in the per-protocol study population

From: Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial

  No infection N = 475 (98.1%) Infection N = 9 (1.9%) All N = 484 P value
Demographics
 Age, mean ± SD, (range), years 62.5 ± 9.0 (33–88) 63.4 ± 6.5 (48–71) 62.5 ± 9.0 (48–71) 0.75
 Race, n (%)     1.0
  White 351 (73.9) 8 (88.9) 359 (74.2)  
  Black 77 (16.2) 1 (11.1) 78 (16.1)  
  Hispanic 27 (5.7) 0 (0.0) 27 (5.6)  
  Other 20 (4.2) 0 (0.0) 20 (4.1)  
Clinical characteristics
 Biopsy result, n (%)     0.609
  Negative 241 (50.7) 4 (44.4) 245 (50.6)  
  Prostate cancer 185 (38.9) 5 (55.6) 190 (39.3)  
  HGPIN 49 (10.3) 0 (0.0) 49 (10.1)  
 History of urinary tract infection, n (%)     0.029
  Yes 50 (10.5) 3 (33.3) 53 (10.9)  
  No 414 (87.2) 5 (55.6) 419 (86.6)  
  Unknown/missing 11 (2.3) 1 (11.1) 12 (2.5)  
 History of urinary retention; n (%)     0.511
  Yes 38 (8.0) 1 (11.1) 39 (8.1)  
  No 387 (81.5) 8 (88.9) 395 (81.6)  
  Unknown/missing 50 (10.5) 0 (0.0) 50 (10.3)  
 FQ usage in prior 2 years, n (%)     0.681
  Yes 109 (22.9) 3 (33.3) 112 (23.1)  
  No 254 (53.5) 4 (44.4) 258 (53.3)  
  Unknown/Missing 112 (23.6) 2 (22.2) 114 (23.6)  
 Hospitalized in prior 1 year; n (%)     0.388
  Yes 44 (9.3) 2 (22.2) 46 (9.5)  
  No 418 (88.0) 7 (77.8) 425 (87.8)  
  Unknown/missing 13 (2.7) 0 (0.0) 13 (2.7)  
 Healthcare worker; n (%)     0.710
  Yes 16 (3.4) 0 (0.0) 16 (3.3)  
  No 406 (85.5) 9 (100.0) 415 (85.7)  
  Unknown/missing 53 (11.2) 0 (0.0) 53 (11.0)  
 Charlson comorbidity score; n (%)     0.144
  0 387 (81.5) 6 (66.7) 393 (81.2)  
  1 16 (3.4) 1 (11.1) 17 (3.5)  
  2 35 (7.4) 0 (0.0) 35 (7.2)  
  3–16 37 (7.8) 2 (22.2) 39 (8.1)  
  1. Abbreviations: HGPIN high-grade prostatic intraepithelial neoplasia, FQ fluoroquinolone